A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 34
- Registration Number
- NCT04220307
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 109
- Registration Number
- NCT04173793
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Long-term Study of AK102 in Patients With Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 796
- Registration Number
- NCT04173403
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 330
- Registration Number
- NCT04173637
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: AK105
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Akeso
- Target Recruit Count
- 31
- Registration Number
- NCT04172571
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 65
- Registration Number
- NCT04172506
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
- Conditions
- MelanomaAdvanced Solid Tumors
- Interventions
- Biological: AK104
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 68
- Registration Number
- NCT04172454
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 96
- Registration Number
- NCT04172233
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 32
- Registration Number
- NCT04169386
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Peking, China
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 10
- Registration Number
- NCT03933293
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China